Micronised progesterone for sleep in transgender women
Short-term effects of micronised progesterone on sleep quality in transfeminine individuals: a randomised, placebo-controlled cross-over trial
Austin Health
38 participants
Jan 4, 2021
Interventional
Conditions
Summary
Transgender individuals seeking feminisation (transfeminine individuals) are treated with estrogen and anti-androgen (testosterone blocker) to align their physical appearance with their gender identity. There has been increasing interest in the potential use of progesterone for transfeminine individuals, given anecdotal reports of improved mood and breast development. This randomised placebo-controlled cross-over trial is a trial of micronised progesterone in transfeminine individuals treated with estradiol therapy. We aim to establish the influence of progesterone on sleep, psychological distress and total testosterone concentration.
Eligibility
Inclusion Criteria1
- Transfeminine individuals aged 18-70 years.
Exclusion Criteria10
- Contraindications to micronised progesterone.
- Sunflower seed allergy.
- Known, suspected, or history of breast cancer.
- Active deep vein thrombosis, pulmonary embolism or history of these conditions.
- Active arterial thromboembolic disease or history of these conditions.
- Known liver dysfunction or disease.
- Recreational drug use, alcohol dependence, known HIV/AIDS or any disease that is
- likely lead to serious illness or death within the study period.
- Inability to understand sufficient English to provide informed consent or participate in
- the trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Micronised progesterone 300mg (3 x 100mg), oral capsule, daily for 1 month Adherence monitored through unused product return There is no intervening wash out period between treatments
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12620001364965